Back to Journals » International Journal of Nanomedicine » Volume 9 » Issue 1

Supercritical fluid-mediated liposomes containing cyclosporin A for the treatment of dry eye syndrome in a rabbit model: comparative study with the conventional cyclosporin A emulsion

Authors Karn PR, Kim HD, Kang H, Sun BK, Jin SE, Hwang SJ

Received 6 April 2014

Accepted for publication 11 May 2014

Published 8 August 2014 Volume 2014:9(1) Pages 3791—3800

DOI https://doi.org/10.2147/IJN.S65601

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Pankaj Ranjan Karn,1 Hyun Do Kim,1,2 Han Kang,1,2 Bo Kyung Sun,1,2 Su-Eon Jin,2 Sung-Joo Hwang1,2

1Yonsei Institute of Pharmaceutical Sciences, 2College of Pharmacy, Yonsei University, Yeonsu-gu, Incheon, Republic of Korea

Background: The objective of this study was to compare the efficacy of cyclosporin (CsA)-encapsulated liposomes with the commercially available CsA emulsion (Restasis®) for the treatment of dry eye syndrome in rabbits.
Methods: Liposomes containing CsA were prepared by the supercritical fluid (SCF) method consisted of phosphatidylcholine from soybean (SCF-S100) and egg lecithins (SCF-EPCS). An in vitro permeation study was carried out using artificial cellulose membrane in Franz diffusion cells. Dry eye syndrome was induced in male albino rabbits and further subdivided into untreated, Restasis®-treated, EPCS, and S100-treated groups. Tear formation in the dry-eye-induced rabbits was evaluated using the Schirmer tear test. All formulations were also evaluated by ocular irritation tests using the Draize eye and winking methods with the determination of CsA concentration in rabbit tears.
Results: After the treatment, the Schirmer tear test value significantly improved in EPCS-treated (P=0.005) and S100-treated (P=0.018) groups compared to the Restasis®-treated group. The AUC0–24 h for rabbit’s tear film after the administration of SCF-S100 was 32.75±9.21 µg·h/mg which was significantly higher than that of 24.59±8.69 µg·h/mg reported with Restasis®. Liposomal CsA formulations used in this study showed lower irritation in rabbit eyes compared with Restasis®.
Conclusion: These results demonstrate that the novel SCF-mediated liposomal CsA promises a significant improvement in overcoming the challenges associated with the treatment of dry eyes.

Keywords: cyclosporin A, liposomes, supercritical fluid, dry eye syndrome

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Cyclosporine A micellar delivery system for dry eyes

Kang H, Cha KH, Cho W, Park J, Park HJ, Sun BK, Hyun SM, Hwang SJ

International Journal of Nanomedicine 2016, 11:2921-2933

Published Date: 21 June 2016

Biodistribution of newly synthesized PHEA-based polymer-coated SPION in Sprague Dawley rats as magnetic resonance contrast agent [Corrigendum]

Park J, Cho W, Park HJ, Cha KH, Ha DC, Choi YW, Lee HY, Cho SH, Hwang SJ

International Journal of Nanomedicine 2014, 9:559-560

Published Date: 20 January 2014

Biodistribution of newly synthesized PHEA-based polymer-coated SPION in Sprague Dawley rats as magnetic resonance contrast agent

Park J, Cho W, Park HJ, Cha KH, Ha DC, Choi YW, Lee HY, Cho SH, Hwang SJ

International Journal of Nanomedicine 2013, 8:4077-4089

Published Date: 31 October 2013

Optimized formulation of solid self-microemulsifying sirolimus delivery systems

Cho W, Kim MS, Kim JS, Park J, Park HJ, Cha KH, Park JS, Hwang SJ

International Journal of Nanomedicine 2013, 8:1673-1682

Published Date: 26 April 2013

Enhancement of the dissolution rate and bioavailability of fenofibrate by a melt-adsorption method using supercritical carbon dioxide

Cha KH, Cho KJ, Kim MS, Kim JS, Park HJ, Park J, Cho W, Park JS, Hwang SJ

International Journal of Nanomedicine 2012, 7:5565-5575

Published Date: 25 October 2012

Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process

Kim MS, Kim JS, Park HJ, Cho WK, Cha KH, Hwang SJ

International Journal of Nanomedicine 2011, 6:2997-3009

Published Date: 24 November 2011

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Acquired hemophilia A: emerging treatment options

Janbain M, Leissinger CA, Kruse-Jarres R

Journal of Blood Medicine 2015, 6:143-150

Published Date: 8 May 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A

Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S

Neuropsychiatric Disease and Treatment 2014, 10:865-867

Published Date: 16 May 2014

Managing hemophilia: the role of mobile technology

Khair K, Holland M

Smart Homecare Technology and TeleHealth 2014, 2:39-44

Published Date: 6 May 2014

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al

International Journal of Nanomedicine 2010, 5:581-591

Published Date: 6 August 2010